List view / Grid view
GlaxoSmithKline plc and Theravance, Inc. announced the start of a…
16 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease...
GlaxoSmithKline plc and Theravance, Inc. announced that the Japanese Ministry…
4 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced that the Japanese Ministry of Health, Labour and Welfare has approved Anoro® Ellipta® (umeclidinium/vilanterol) for the relief of various symptoms due to airway obstruction with chronic obstructive pulmonary diseases...
GlaxoSmithKline plc and Theravance, Inc. announced positive results from three…
14 March 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced positive results from three phase III studies...
GlaxoSmithKline plc and Theravance, Inc. announced that recruitment of patients…
14 March 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced that recruitment of patients into the “Study to Understand Mortality and MorbidITy”, known as SUMMIT, has completed enrolment...
RELVAR® ELLIPTA® is now licensed across 31 European countries...
18 November 2013 | By GlaxoSmithKline
RELVAR® ELLIPTA® is now licensed across 31 European countries...
GSK and Theravance, Inc. announced that the PADAC to the…
10 September 2013 | By GlaxoSmithKline
GSK and Theravance, Inc. announced that the PADAC to the US FDA voted 11 yes to 2 no that the efficacy and safety data provide substantial evidence to support approval of umeclidinium/vilanterol...
GlaxoSmithKline and Theravance announced that the US FDA has approved…
10 May 2013 | By GlaxoSmithKline
GlaxoSmithKline and Theravance announced that the US FDA has approved BREO™ ELLIPTA™...
Results from the pivotal efficacy studies...
2 July 2012 | By GlaxoSmithKline
Results from the pivotal efficacy studies...
GSK and Theravance, Inc. announced the completion of the phase…
9 January 2012 | By GlaxoSmithKline
GSK and Theravance, Inc. announced the completion of the phase III registration programme...
